건선 치료제 시장 : 약제 클래스별, 투여 경로, 건선 유형, 환자층, 유통 채널, 치료 환경별 - 세계 예측(2026-2032년)

The Psoriasis Drugs Market is projected to grow by USD 34.50 billion at a CAGR of 10.85% by 2032.

Psoriasis drugs are moving from broad immunosuppression toward precision dermatology, with treatment decisions increasingly shaped by disease severity, comorbid psoriatic arthritis, prior biologic exposure, route of administration, payer access, and patient preference. Psoriasis is recognized by the World Health Organization as a chronic, immune-mediated, noncommunicable disease with systemic impact, and peer-reviewed epidemiology consistently places global prevalence at roughly 2% to 3%, with meaningful variation by geography, ancestry, age, and diagnostic access.

The psoriasis therapeutics landscape spans topical corticosteroids and vitamin D analogs, phototherapy-adjacent care, oral systemic therapies such as methotrexate, cyclosporine, apremilast, deucravacitinib, and targeted biologics directed at TNF-alpha, IL-17, IL-12/23, and IL-23 pathways. Demand is being driven by higher diagnosis rates, expanding biologic eligibility, biosimilar adoption, longer-term safety evidence, and patient expectations for durable skin clearance, lower treatment burden, and convenient dosing.

Transformative Shifts in the Psoriasis Treatment Landscape

The competitive landscape is being reshaped by interleukin-focused biologics that have raised clinical expectations from symptom control to high levels of skin clearance, including PASI 90 and PASI 100 outcomes reported in pivotal trials. IL-23 and IL-17 inhibitors have strengthened the standard of care for moderate-to-severe plaque psoriasis, while oral innovation, including TYK2 inhibition, is widening options for patients who prefer noninjectable therapies or are not ready for biologic treatment.

At the same time, biosimilars are altering pricing dynamics in TNF-alpha therapy and encouraging payers to revisit formulary design, step therapy, and prior authorization criteria. Dermatology practices are adapting to more complex sequencing decisions as clinicians balance efficacy, infection risk, inflammatory bowel disease considerations, psoriatic arthritis activity, cardiometabolic comorbidities, pregnancy planning, and long-term adherence.

Cumulative Impact of Artificial Intelligence on Psoriasis Drugs

Artificial intelligence is becoming a practical force in psoriasis drug development, commercialization, and care delivery. In research, AI-enabled image analysis can support more objective severity assessment using clinical photography, while machine learning models are being explored to stratify patients by treatment response, comorbidity risk, flare probability, and adherence patterns. These tools may reduce variability in PASI scoring and improve trial enrichment when validated against dermatologist-led assessments.

For manufacturers and healthcare systems, AI can improve pharmacovigilance signal detection, medical information workflows, real-world evidence generation, claims analytics, and patient support personalization. However, adoption must remain clinically governed because psoriasis datasets can underrepresent darker skin tones and underserved populations, creating bias risks in diagnostic tools, severity algorithms, and digital triage platforms.

Key Regional Insights Across Major Psoriasis Drug Markets

North America remains a leading region for psoriasis drugs because of high biologic utilization, strong specialist access, advanced payer management, and rapid uptake of FDA-approved targeted therapies in the United States and Canada. Europe combines broad dermatology expertise with stringent health technology assessment, making reimbursement evidence, comparative effectiveness, treatment guidelines, and biosimilar value central to access across the European Union and the United Kingdom.

Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia improve specialty care capacity and increase access to biologics and oral targeted therapies, although affordability, reimbursement depth, and urban-rural dermatology access vary widely. Latin America, led by Brazil and Mexico, shows rising demand for advanced therapies but remains sensitive to public procurement, reimbursement delays, and out-of-pocket costs. The Middle East, particularly GCC markets, is investing in specialty care infrastructure and centralized access pathways, while Africa continues to face diagnosis gaps, uneven dermatology access, and limited availability of high-cost biologics outside major urban centers.

Key Group Insights for Psoriasis Drug Access and Growth

Within ASEAN, psoriasis drug demand is influenced by growing dermatology networks, private hospital expansion, medical tourism in selected markets, and variable reimbursement across Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC benefits from high healthcare investment, centralized procurement, national insurance reforms, and increasing specialist availability, supporting access to biologics for eligible moderate-to-severe patients.

The European Union is shaped by coordinated regulatory standards, country-level reimbursement negotiations, clinical guideline adoption, and strong biosimilar policies that influence pricing and access. BRICS markets represent a major long-term opportunity because of large patient pools, expanding local pharmaceutical capabilities, and rising specialist care capacity, though affordability and public funding remain decisive. G7 countries continue to set clinical, regulatory, and pharmacovigilance benchmarks, while NATO member markets overlap substantially with advanced North American and European systems where supply resilience, quality standards, reimbursement scrutiny, and medicine security are prominent.

Key Country Insights in Psoriasis Drug Commercialization

The United States is the most innovation-intensive psoriasis drug market, supported by FDA approvals, specialty pharmacy channels, dermatology biologic experience, and broad use of targeted therapies, though payer controls strongly influence treatment sequencing. Canada emphasizes evidence-based reimbursement and provincial access decisions, while Mexico and Brazil show increasing demand for advanced dermatology care amid public-sector budget constraints, uneven access, and affordability pressure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are characterized by strong guideline adoption, health technology assessment, structured reimbursement, and growing biosimilar use, while Russia faces more localized access, registration, and procurement dynamics. China is expanding access through regulatory modernization, accelerated review pathways, and national reimbursement mechanisms; India remains highly price-sensitive with growing specialist adoption in urban centers; Japan and South Korea maintain sophisticated dermatology markets with strong clinical governance; and Australia benefits from structured reimbursement through established public funding mechanisms that support eligible patients with moderate-to-severe disease.

Actionable Recommendations for Psoriasis Drug Industry Leaders

Industry leaders should prioritize differentiated clinical value rather than relying solely on class participation. Evidence packages should address high skin clearance, durability, speed of onset, long-term safety, psoriatic arthritis relevance, quality-of-life improvement, and real-world persistence. Manufacturers also need stronger market access planning that anticipates biosimilar competition, step edits, prior authorization, and payer demand for comparative outcomes.

Organizations should invest in inclusive clinical trials, skin-of-color evidence, patient support programs, digital adherence tools, and education that reduces treatment discontinuation and underdiagnosis. Regional strategies must reflect reimbursement realities: value dossiers for Europe, payer navigation in North America, affordability models in emerging markets, tender readiness in public procurement systems, and evidence generation that supports both clinical confidence and equitable access.

Research Methodology for Psoriasis Drugs Analysis

This executive summary is based on a secondary-research framework using publicly available and verifiable sources, including regulatory agency information, peer-reviewed dermatology literature, clinical trial publications, treatment guidelines, epidemiology references, pharmacovigilance updates, and health technology assessment patterns. Sources considered include organizations such as the World Health Organization, U.S. Food and Drug Administration, European Medicines Agency, national dermatology associations, and published clinical evidence on psoriasis biologics, biosimilars, oral systemic therapies, and targeted immune modulators.

The analysis integrates therapeutic class dynamics, regional access conditions, policy factors, technology trends, and real-world care considerations. It avoids unsupported market-size claims and emphasizes evidence-backed drivers such as psoriasis prevalence, biologic innovation, biosimilar uptake, reimbursement controls, comorbidity management, and AI-enabled clinical and commercial applications.

Conclusion: Future Direction of the Psoriasis Drugs Market

The psoriasis drugs market is entering a more competitive, evidence-driven phase where durable clearance, convenience, safety, affordability, and access are all decisive. Targeted biologics and oral immune modulators have transformed expectations for moderate-to-severe plaque psoriasis, while biosimilars, health technology assessment, and payer policies are reshaping commercial strategy.

Future success will depend on proving differentiated value across diverse patient populations and healthcare systems. Organizations that combine strong clinical evidence, equitable access planning, AI-enabled insights, inclusive real-world data, and disciplined regional execution will be best positioned to lead in the evolving psoriasis therapeutics landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Psoriasis Drugs Market, by Drug Class

• 7.1. Biologics
  • 7.1.1. IL 17 Inhibitors
  • 7.1.2. IL 23 Inhibitors
  • 7.1.3. TNF Inhibitors
• 7.2. Small Molecules
  • 7.2.1. JAK Inhibitors
  • 7.2.2. PDE4 Inhibitors

8. Psoriasis Drugs Market, by Route Of Administration

• 8.1. Injectable
  • 8.1.1. Intravenous
  • 8.1.2. Subcutaneous
• 8.2. Oral
  • 8.2.1. Capsules
  • 8.2.2. Suspensions
  • 8.2.3. Tablets
• 8.3. Topical
  • 8.3.1. Creams
  • 8.3.2. Foams
  • 8.3.3. Gels
  • 8.3.4. Ointments

9. Psoriasis Drugs Market, by Psoriasis Type

• 9.1. Erythrodermic Psoriasis
• 9.2. Guttate Psoriasis
• 9.3. Inverse Psoriasis
• 9.4. Nail Psoriasis
• 9.5. Plaque Psoriasis
• 9.6. Pustular Psoriasis
• 9.7. Scalp Psoriasis

10. Psoriasis Drugs Market, by Patient Type

• 10.1. Adults
• 10.2. Geriatric
• 10.3. Pediatric

11. Psoriasis Drugs Market, by Distribution Channel

• 11.1. Hospital Pharmacies
• 11.2. Online Pharmacies
• 11.3. Retail Pharmacies
• 11.4. Specialty Pharmacies

12. Psoriasis Drugs Market, by Treatment Setting

• 12.1. Home-Based Treatment
• 12.2. Hospital-Based Care
• 12.3. Specialty Dermatology Clinics

13. Psoriasis Drugs Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Psoriasis Drugs Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Psoriasis Drugs Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AbbVie Inc.
• 17.2. Almirall S.A.
• 17.3. Amgen Inc
• 17.4. AstraZeneca PLC
• 17.5. Bausch Health Companies Inc.
• 17.6. Biogen Inc.
• 17.7. Boehringer Ingelheim International GmbH
• 17.8. Bristol-Myers Squibb Company
• 17.9. Celltrion, Inc.
• 17.10. Dermavant Sciences Ltd.
• 17.11. Eli Lilly and Company
• 17.12. Fresenius Kabi AG
• 17.13. GlaxoSmithKline plc
• 17.14. Glenmark Pharmaceuticals Ltd.
• 17.15. Incyte Corporation
• 17.16. Johnson & Johnson Services, Inc.
• 17.17. LEO Pharma A/S
• 17.18. Lupin Limited
• 17.19. Merck & Co., Inc.
• 17.20. Mitsubishi Tanabe Pharma Corporation
• 17.21. Novartis AG
• 17.22. Pfizer Inc.
• 17.23. Samsung Bioepis Co., Ltd.
• 17.24. Sanofi S.A.
• 17.25. Sun Pharmaceutical Industries Ltd
• 17.26. Takeda Pharmaceutical Company Limited
• 17.27. UCB S.A.
• 17.28. Viatris Inc.